<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Clinical Neurosciences</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/10F02908-7312-42BE-BC50-57C32C14F85A"><gtr:id>10F02908-7312-42BE-BC50-57C32C14F85A</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Miller</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A272DBEA-0D1F-4203-B758-69698FC352F1"><gtr:id>A272DBEA-0D1F-4203-B758-69698FC352F1</gtr:id><gtr:firstName>Siddharthan</gtr:firstName><gtr:surname>Chandran</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/147A4A54-6D76-463F-99BD-C21F5AB451A4"><gtr:id>147A4A54-6D76-463F-99BD-C21F5AB451A4</gtr:id><gtr:firstName>Alastair</gtr:firstName><gtr:surname>Compston</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/29617405-8FC1-49EC-A600-3D1C5032A458"><gtr:id>29617405-8FC1-49EC-A600-3D1C5032A458</gtr:id><gtr:firstName>Alasdair</gtr:firstName><gtr:surname>Coles</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F89B2461-11DD-4E45-84EE-D5780979AFD9"><gtr:id>F89B2461-11DD-4E45-84EE-D5780979AFD9</gtr:id><gtr:firstName>Alan</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Thompson</gtr:surname><gtr:orcidId>0000-0002-4333-8496</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0502107"><gtr:id>5AD719C4-E672-4E49-8434-609BA5BB6CBD</gtr:id><gtr:title>Autologous adult human mesenchymal stem cells: a neuroprotective therapy for multiple sclerosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0502107</gtr:grantReference><gtr:abstractText>MS is a disease where nerves and its insulation layer are damaged leading to symptoms. Over time the nerve damage accumulates leading to fixed and progressive disability in the vast majority of patients. Therapies for MS presently are limited only to partially reducing the frequency of individual attacks. There are no effective treatments to protect the nerves. This study is trying to explore whether stem cells taken from the patients bone marrow or skin could through a cell infusion (similar to blood transfusion) protect the nerves of the MS patient.</gtr:abstractText><gtr:technicalSummary>Multiple sclerosis (MS) is the commonest cause of neurological disability in young adults. It is a cause of significant morbidity and mortality in the industrialised world with prevalence estimates ranging from 110-175 per 100 000 in the UK. It is a multifocal and multiphasic immune mediated disease characterised pathologically by inflammatory demyelination, axonal injury and partial remyelination. Therapeutic treatments of MS thus have two aims; to prevent (disease modifying) and to repair damage that has already occurred. Although some advances in treatment to reduce relapse rate have been made in the last decade, little has been achieved in terms of definitive treatments for relapse, prevention or repair of fixed disability and disease progression. The lack of such therapies represents a substantial gap in the treatment of MS. There is a need to develop treatments that prevent axonal loss, the primary correlate of clinical disability. This first into man proposal builds on our existing expertise on somatic adult stem cells, immune treatment of MS and non-invasive imaging markers of axonal loss and remyelination. A series of studies using animal models of MS have demonstrated neuroprotection following intravenous delivery of precursor cells. We propose to define an initial cohort of patients and using a cross-over trial design will examine the neuroprotective therapeutic potential of intravenously administered autologous adult human mesenchymal stem cells. Our approach is to identify prospectively cohorts with clinically articulate lesions involving the optic nerve in which detailed protocols can be subsequently evaluated for screening the outcome of a more widely distributed neuroprotective cellular therapy, extrapolating the experience of the sentinel lesion to the disease as a whole. The optic nerve is our favoured target given its clinical eloquence and the ready access to neurophysiological and serial quantitative imaging outcomes. This proposal addresses several areas highlighted by the grant call being a proof of concept study to examine the neuroprotective therapeutic potential of intravenously administered autologous adult human mesenchymal stem cells in MS.</gtr:technicalSummary><gtr:fund><gtr:end>2010-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>692405</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Haematology</gtr:department><gtr:description>MSC generation</gtr:description><gtr:id>6409E0A0-84ED-4D71-9B2D-8C76B7B31DF3</gtr:id><gtr:impact>Multi-disciplinary. Research publications</gtr:impact><gtr:outcomeId>pqb7EMehzFS-1</gtr:outcomeId><gtr:partnerContribution>Hugely, understanding of principles of GMP for cell manufacture</gtr:partnerContribution><gtr:piContribution>Patient sample derivation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>Paolo Imperial</gtr:description><gtr:id>D7AFAB6B-8AF8-4B3F-AF1E-03F9714FA3A1</gtr:id><gtr:impact>Successfui award of grant MSS/SCF for trial to recruit 2012</gtr:impact><gtr:outcomeId>Euef1s4A1Vu-1</gtr:outcomeId><gtr:partnerContribution>Methods for patient selection, trial design, measuring neuroprotection</gtr:partnerContribution><gtr:piContribution>Trial design, protocol development, patient stratification</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Parliamentary visit</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1268867D-1E26-4810-8482-042EDC476737</gtr:id><gtr:impact>Formal lobbying at Parliament as part of a MS Society sponsored delegation

Engagement, parliamentary question tabled</gtr:impact><gtr:outcomeId>87AE9250AC5</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9CD02686-3DE5-48EB-95F2-D456BA3BB877</gtr:id><gtr:impact>Open public lecture at Edinburgh attended by 250 people

Public engagement</gtr:impact><gtr:outcomeId>19133B4CBC7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Academic talks</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1F1F8D48-8579-402C-8CD0-E8F669550783</gtr:id><gtr:impact>Academic presentations and workshops including MRC - British Council in Germany

Engagement - potential collaborations</gtr:impact><gtr:outcomeId>6C4FE08D159</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MS Society Forums</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5ED6738A-5842-48A2-A2EC-4AD2A326FBC2</gtr:id><gtr:impact>Public lectures

Public engagement</gtr:impact><gtr:outcomeId>797EDFB0F19</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Third sector organisations</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient AGMs</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B99ABDD5-3B59-412B-97FA-8D58B482C54A</gtr:id><gtr:impact>Q &amp;amp; A, lots of discussion and follow up around patient participation in research, trials and ethics therein

As above</gtr:impact><gtr:outcomeId>BbSgodjGTYs</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2009,2010,2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC iPS addendum</gtr:description><gtr:end>2008-11-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>513A23C0-44D1-49E5-8C94-4CBCA0A7BF50</gtr:id><gtr:outcomeId>51AA59935240</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>125000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Evelyn Trust, Project Grant</gtr:description><gtr:end>2010-06-02</gtr:end><gtr:fundingOrg>The Evelyn Trust</gtr:fundingOrg><gtr:id>2360C881-6271-496D-88E2-AC726A7C38C9</gtr:id><gtr:outcomeId>870B3132FC40</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MS Society Project Grant</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>Multiple Sclerosis Society</gtr:fundingOrg><gtr:id>EA3F0A01-BB8A-46AB-A0ED-DF10513B9B51</gtr:id><gtr:outcomeId>EF5825634B40</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Advised and chair Multiple Sclerosis Society Panel on a unified UK strategy on potential bone marrow transplantation therapies for MS</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F6B01B68-0E8B-4AD3-894F-531C43FE3FCC</gtr:id><gtr:outcomeId>58c91a0b3a3f02.06170532</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6B4B07D7-9542-42CB-B287-A241B07F6B6C</gtr:id><gtr:title>Patterns of cognitive dysfunction in progressive MS.</gtr:title><gtr:parentPublicationTitle>Behavioural neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/958f16ec91fcad61262b44e2ab80a6d3"><gtr:id>958f16ec91fcad61262b44e2ab80a6d3</gtr:id><gtr:otherNames>Connick P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0953-4180</gtr:issn><gtr:outcomeId>pm_16376_26_23548884</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBFAABDF-59DB-4B2E-89A5-67E0C63AB4F0</gtr:id><gtr:title>PATTERNS OF COGNITIVE DYSFUNCTION IN PROGRESSIVE MULTIPLE SCLEROSIS</gtr:title><gtr:parentPublicationTitle>Journal of Neurology, Neurosurgery &amp; Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/958f16ec91fcad61262b44e2ab80a6d3"><gtr:id>958f16ec91fcad61262b44e2ab80a6d3</gtr:id><gtr:otherNames>Connick P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_16376_26_24108948</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FEE24EA-BC46-4566-A2F1-9336E0F10F22</gtr:id><gtr:title>AUTOLOGOUS MESENCHYMAL STEM CELLS FOR THE TREATMENT OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS: AN OPEN-LABEL PHASE 2A PROOF-OF-CONCEPT STUDY</gtr:title><gtr:parentPublicationTitle>Journal of Neurology, Neurosurgery &amp; Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/958f16ec91fcad61262b44e2ab80a6d3"><gtr:id>958f16ec91fcad61262b44e2ab80a6d3</gtr:id><gtr:otherNames>Connick P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_16376_26_24109005</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>090B6766-FF9F-4CE3-B53F-413E28FE47EA</gtr:id><gtr:title>The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group.</gtr:title><gtr:parentPublicationTitle>Multiple sclerosis (Houndmills, Basingstoke, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0cfe13cb82a75494aa2e6a7563bd5f95"><gtr:id>0cfe13cb82a75494aa2e6a7563bd5f95</gtr:id><gtr:otherNames>Freedman MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1352-4585</gtr:issn><gtr:outcomeId>TGDcDmURS7V</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D5EEE4D-F1DA-4B0C-BD8E-C68C2DA3C71D</gtr:id><gtr:title>Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/958f16ec91fcad61262b44e2ab80a6d3"><gtr:id>958f16ec91fcad61262b44e2ab80a6d3</gtr:id><gtr:otherNames>Connick P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>pm_16376_26_22236384</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1ADC503-CD82-4F59-A8CD-024C163E653D</gtr:id><gtr:title>Verbal fluency as a rapid screening test for cognitive impairment in progressive multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/958f16ec91fcad61262b44e2ab80a6d3"><gtr:id>958f16ec91fcad61262b44e2ab80a6d3</gtr:id><gtr:otherNames>Connick P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>sfYzpeC6z3U</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCEB2575-F4C9-4757-B06C-36A270D11803</gtr:id><gtr:title>What are the prospects of stem cell therapy for neurology?</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/831cef59561581891915c23533bdd156"><gtr:id>831cef59561581891915c23533bdd156</gtr:id><gtr:otherNames>Chandran S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>585d4e6112ca52.99098532</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4D002D9-9A6A-4EFD-A998-6F44AFC45AE7</gtr:id><gtr:title>The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/958f16ec91fcad61262b44e2ab80a6d3"><gtr:id>958f16ec91fcad61262b44e2ab80a6d3</gtr:id><gtr:otherNames>Connick P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>aBEzz6v8y52</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0502107</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>0CDFB83C-594C-4860-B0BE-C82CA4D45B6B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>